thymosin alpha 1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
=== Military archives === The Defence Historical Service (SHD), located at the Château de Vincennes, preserves military personnel files. Many of these files contain copies, sometimes complete, of Parisian civil records. The online databases include name indexes for officer career records. On-site, one can consult muster rolls for all army units, which record each soldier’s date and place of birth, residence, and the names of parents and spouses. The Paris Archives also retain documents on military recruitment in the Seine department, including alphabetical tables (1872–1940) and muster rolls (1887–1921). These archives are accessible online.
=== Ion implantation === Ion implantation has been used to create silver nanoparticles embedded in glass, polyurethane, silicone, polyethylene, and poly(methyl methacrylate). Particles are embedded in the substrate by means of bombardment at high accelerating voltages. At a fixed current density of the ion beam up to a certain value, the size of the embedded silver nanoparticles has been found to be monodisperse within the population, after which only an increase in the ion concentration is observed. A further increase in the ion beam dose has been found to reduce both the nanoparticle size and density in the target substrate, whereas an ion beam operating at a high accelerating voltage with a gradually increasing current density has been found to result in a gradual increase in the nanoparticle size. There are a few competing mechanisms which may result in the decrease in nanoparticle size; destruction of NPs upon collision, sputtering of the sample surface, particle fusion upon heating and dissociation. The formation of embedded nanoparticles is complex, and all of the controlling parameters and factors have not yet been investigated. Computer simulation is still difficult as it involves processes of diffusion and clustering, however it can be broken down into a few different sub-processes such as implantation, diffusion, and growth. Upon implantation, silver ions will reach different depths within the substrate which approaches a Gaussian distribution with the mean centered at X depth.
==== Declined ==== Jasmine Crockett, incumbent U.S. representative from the 30th district (ran for U.S. Senate, endorsed Haynes III) Marc Veasey, incumbent U.S. representative from the 25th district (ran for Tarrant County judge)
== Collaborations == In 2013, La Colombe partnered with the Clinton Foundation to found the Haiti Coffee Academy. The organization's stated aim is to improve coffee growers’ livelihoods in Haiti through training programs for smallholder farmers, a demonstration farm and nursery, and efforts to strengthen the supply chain for both local and export markets for Haitian coffee. In 2016, La Colombe collaborated with Yards Brewing Company, also in the Philadelphia area, to produce a coffee stout to be served in local Shake Shack branches. Also in 2016, the company collaborated with the Icelandic brewer Einstök and again with Yards on Snorri's Awakening, a coffee pale ale. In 2021, the company collaborated with Whole Foods Market to open new stores in New York City and Austin.
According to UN estimates, the war has directly caused the deaths of over 3,000 children as of December 2020; while indirect causes of the war (lack of food, health and infrastructure) have led to additional deaths. The UN estimates that at the end of 2021, 70% of all the casualties of the war (around 259,000) are children under five. Yemeni refugee women and children are extremely susceptible to smuggling and human trafficking. NGOs report that vulnerable populations in Yemen were at increased risk for human trafficking in 2015 because of ongoing armed conflict, civil unrest, and lawlessness. Migrant workers from Somalia who remained in Yemen during this period suffered from increased violence, and women and children became most vulnerable to human trafficking. Prostitution of women and child sex slaves is a social issue in Yemen. Citizens of other gulf states are beginning to be drawn into the sex tourism industry. The poorest people in Yemen work locally and children are commonly sold as sex slaves abroad. While this issue is worsening, the plight of Somalis in Yemen has been ignored by the government. Emphasizing the dire humanitarian needs of about 23.4 million people, UNFPA reported the lack of access to sexual and reproductive health and protection services, and exposure to death in pregnancy and childbirth and life-threatening violence. An increase in child marriage as a coping mechanism by impoverished families as the conflict continues was also reported.
Sources: en.wikipedia.org
== References == Hahn, Theophilus (1881) Tsuni-Goam, the Supreme Being of the Khoi-Khoi Trübner, London; Kidd, Dudley (1904) The Essential Kafir A. and C. Black, London; Massey, Gerald (1881) Book of the Beginnings, containing an attempt to recover and reconstitute the lost origines [sic] of the myths and mysteries, types and symbols, religion and language, with Egypt for the mouthpiece and Africa as the birthplace Williams and Norgate, London;
In 80–85% of cases, the ALK detected in ALK-positive ALCL is a NPM1-ALK fusion protein. It is made by a fusion of NPM1 gene, which makes nucleophosmin 1, located on the long or "q" arm of chromosome 5 at position 35 (notated as 5q35) with the ALK gene located on the short or "p" arm of chromosome 2 at position 23 (notated as 2p23) to form a chimeric gene notated as (2;5)(p23;q35). In 13% of cases ALK fuses with the TPM3 gene or in <1% of cases for each of the following genes: TFG, ATIC, CLTC, TPM4, MSN, RNF213 (also termed ALO17), MYH9, or TRAF1. All of these fusion proteins are considered to act like NPMI-ALK in possessing high ALK activity that promotes the development and progression ALK-positive ALCL by activating the cell signaling pathways cited in the Introduction. 15% Of individuals with ALK-positive ALCL also have point mutations in the NOTCH1 gene. While most of these abnormalities are thought to be detrimental not all are. For example, DUSP22 gene rearrangements are associated with favorable outcomes in ALK-positive (as well as ALK-negative) ALCL.
A composite cross population (CCP) is created by crossing a number of plants from different lines, and subsequently bulking seeds from the resulting offspring. This makes a CCP a population of plants with a lot of inherent genetic diversity, in contrast to monocultures where all plants are clones and homozygous at all loci (fully inbred). In recent years CCPs have been proposed as a way to create modern landraces of wheat, barley and oats. Research is done to explore whether they are better suited for organic farming than the modern cultivars. They are suited for participatory breeding of crops, which is in contrast to cultivars owned by big breeding companies. The idea of using CCPs in plant breeding was published in 1956 based on the barley composite cross devised by Harry Harlan and Mary Martini in 1929. Yield data for 4 different populations for 8–28 years were presented in the article and after 8–15 years of repeated breeding under natural selection, the populations out-yielded the reference cultivar.
Approximately 0.2 to 1% of people have a "weak D" phenotype, meaning that they are positive for the RhD antigen, but exhibit weak or negative reactions with some anti-RhD reagents due to decreased antigen expression or atypical variants of antigen structure. If routine serologic testing for RhD results in a score of 2+ or less, the antiglobulin test can be used to demonstrate the presence of RhD. Weak D testing is also performed on blood donors who initially type as RhD negative. Historically, blood donors with weak D were treated as Rh positive and patients with weak D were treated as Rh negative in order to avoid potential exposure to incompatible blood. Genotyping is increasingly used to determine the molecular basis of weak D phenotypes, as this determines whether or not individuals with weak D can produce antibodies against RhD or sensitize others to the RhD antigen.
Sources: en.wikipedia.org
The antiandrogenic activity of CPA is dose-dependent. Although CPA is a potent antiandrogen, relatively high doses of CPA are nonetheless required for clinically important AR antagonism. The clinical antiandrogenic efficacy of birth control pills containing CPA, which have only low doses of CPA in them (2 mg/day), often can't be distinguished from that of birth control pills containing other progestins. It is likely that the antiandrogenic effects of CPA-containing birth control pills are due mostly to the ethinylestradiol component and/or suppression of androgen levels, rather than the antiandrogenic activity of the small doses of CPA present in them. CPA has been found to decrease inflammatory acne lesions in males by about 15% at 5 mg/day, by 45% at 25 mg/day, and by 73% at 100 mg/day. A dosage of 100 mg/day CPA can achieve a 65 to 70% reduction in sebum excretion rate in males within 4 weeks of treatment, but doses of 10 mg/day CPA or less are said to have a negligible effect. On the basis of these findings, it has estimated that the threshold dosage of CPA to reduce sebum production may be 5 mg/day in males. In other studies, 25 mg/day CPA resulted in substantial improvement or complete clearance of severe acne in almost all males, whereas 12.5 mg/day was ineffective. CPA has been found to be strongly catabolic in young healthy males. It was shown to result in a mean negative nitrogen balance of 1.2 g at 50 mg/day, 1.4 g at 100 mg/day, and 2.5 g at 200 mg/day. This corresponded to mean losses of lean tissue of 780, 945, and 1,515 g, respectively.
Three whales die after the pod of about 30 whales re-stranded at Pūponga Beach in Golden Bay despite efforts to refloat them. 20 January – A second pod of about 11 whales is stranded near Taupata Point in the Golden Bay. 21 January – DOC staff and volunteers succeed in refloating the initial pod of 30 whales and ten whales from the second pod. One of the whales from the second pod dies. 22 January: Ten whales are re-stranded in Golden Bay, prompting a response from DOC and volunteers. The Body Shop NZ goes into voluntary administration. Media company NZME announces plans to cut 14 reporting and 24 production jobs as part of a restructuring process. 23 January: DOC staff, Project Jonah and community volunteers succeed in refloating the ten stranded whales in Golden Bay. Prime Minister Luxon gives his State of the Nation address. He announces that the existing Crown Research Institutes will be merged into three new Public Research Organisations and that the Government will establish a new foreign investment agency. 25 January – A tornado and severe storm hits Mangawhai and surrounding areas, causing two serious injuries, damage to about 50 properties and power outages affecting 4,700 homes. 27 January: In order to attract digital nomads, a 'digital nomad' visa is announced to allow non-residents to work in New Zealand for up to nine months, given they work entirely remotely for a non-New Zealand company. The work will be untaxed for up to 90 days.
=== Injection loop === The injection loop is a segment of tubing of known volume which is filled with the sample solution before it is injected into the column. Loop volume can range from a few microliters to 50 ml or more.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.